# Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation

> **NCT04720742** · PHASE2 · WITHDRAWN · sponsor: **IrsiCaixa**

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Analytical Treatment Interruption + bNAbs infusion

## Key facts

- **NCT ID:** NCT04720742
- **Lead sponsor:** IrsiCaixa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-28
- **Primary completion:** 2022-03-28
- **Final completion:** 2022-03-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the COVID-19 pandemic the financial sponsor of the trial suspended the study funding due to funding limitations and based on various considerations, including the uncertainties of conducting the study in the volatile scenario of this pandemic.
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720742, "Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04720742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*